Skip to main content
Hayan Yoon headshot

Hayan Yoon

Partner
Intellectual Property

Hayan provides comprehensive patent guidance to her clients, specializing in advising emerging growth and publicly traded life science companies and venture capital firms on various aspects of strategic intellectual property and patent counseling.
 

Hayan's representative experience includes IP diligence in the following deals:

  • Royalty Pharma on IP diligence in its $525 million purchase of royalties for ImmuNext's frexalimab
  • Pharmakon’s non-dilutive term loan financing for ImmunoGen for up to $175 million
  • Pharmakon’s $100 million loan agreement with Immunocore
  • Passage Bio’s $110 million series B financing and initial and follow-on public offerings
  • Impel Pharmaceuticals’ sale to JN BIDCO LLC
  • Adaptive Biotechnologies’ $345 million initial public offering

Hayan has an in-depth grasp of the life sciences industry and corporate goals. She leverages her significant scientific and legal experience in life sciences to counsel clients related to U.S. and foreign patent prosecution and management, patent strategy, IP diligence pre-litigation assessment, post-issuance proceeding, and validity and infringement opinions. She has extensive experience in assessing competitive IP landscapes and complex IP assets and advising strategies for improving IP assets while mitigating risks.

Before her legal career, Hayan was a postdoctoral fellow at UC Berkeley and the Damon Runyon Cancer Research Foundation, and a researcher at a gene therapy company. She maintains her passion for life sciences while providing counsel to her clients in the life science industry.

We have extensively worked with Hayan Yoon who is very thoughtful and creative when it comes to determining our IP strategy, and has been very successful with this. She is able to work well with the examiners and find an agreeable upon path to success with complicated matters."
Client Commentator, The Legal 500
2024